Physician profile
John M Klein
NPI 1528071172
$5,276.45
in general payments reported to CMS, 2019-2025
38 companies · $631 in 2025
The $631 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $881 · 2021: $1,033 · 2022: $639 · 2023: $453 · 2024: $484 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.41 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $573.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $487.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $462.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $321.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $300.71 | 2019-2023 | Verquvo |
| Pfizer INC. | $293.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.88 | 2019-2025 | Jardiance |
| Amgen INC. | $234.02 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $210.65 | 2019-2022 | |
| Mylan Specialty L.P. | $111.14 | 2020-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $110.03 | 2021-2023 | |
| Exact Sciences Corporation | $108.30 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $107.87 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.19 | 2019-2025 | Xifaxan |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $98.63 | 2021-2025 | |
| Allergan, INC. | $83.80 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $76.56 | 2019-2020 | |
| Genentech USA, INC. | $62.37 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $57.09 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $47.53 | 2024-2025 | Zenpep |
| Abbvie INC. | $46.72 | 2021-2022 | |
| Abbott Laboratories | $29.56 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $28.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $26.60 | 2021 | |
| Bioventus LLC | $24.84 | 2023 | Durolane |
| Sumitomo Pharma America, INC. | $23.02 | 2025 | Gemtesa |
| Optinose US, INC. | $22.61 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.33 | 2022 | |
| Almatica Pharma LLC | $18.02 | 2021 | |
| Inspire Medical Systems, INC. | $17.10 | 2025 | Inspire |
| Acadia Pharmaceuticals INC | $16.97 | 2025 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $16.85 | 2019 | |
| Philips North America LLC | $14.59 | 2022 | |
| Angiodynamics, INC. | $13.78 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.52 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.